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Abstract
The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study was
the first trial to assess whether statins might be of clinical benefit in those with recently unstable
coronary disease. MIRACL found that high-dose atorvastatin was safe and reduced the incidence
of the composite endpoint, death, non-fatal myocardial infarction, resuscitated sudden cardiac
death or emergent rehospitalization for recurrent ischemia at 16 weeks when compared with
placebo. Despite a number of important study limitations, MIRACL's findings and the prior
observation that inpatient initiation of lipid-lowering therapy is associated with higher rates of
subsequent utilization, suggest that it is prudent to begin statin therapy when patients present with
an acute coronary syndrome.
The problem
Three published [1–3] and one recently presented [4] ran-
domized placebo-controlled clinical trial have unequivo-
cally demonstrated that 3-Hydroxy-3-methylgluatryl
coenzyme A (HMG CoA) reductase inhibitors (statins) re-
duce the morbidity and mortality associated with coro-
nary disease. These trials found that when compared with
placebo, statins significantly reduced the incidence of
death, myocardial infarction, unstable angina, percutane-
ous and surgical coronary revascularization, and stroke in
persons with stable coronary disease. Because patients who
had experienced an acute coronary syndrome within three
to six months of enrollment were excluded, these trials
did not assess the effect of lipid-lowering therapy on ad-
verse cardiovascular events in those with recently unstable
coronary disease. Whether lipid-lowering therapy would
provide incremental benefit if initiated immediately fol-
lowing an acute coronary syndrome is an important issue
as the risk of a recurrent adverse cardiac events is much
greater in patients with unstable coronary disease than in
the stable setting. The Myocardial Ischemia Reduction
with Aggressive Cholesterol Lowering (MIRACL) trial set
out to answer this question.
The answer?
MIRACL enrolled 3,086 patients within 24–96 hours
(mean 63 hours) of admission for unstable angina or a
non-Q-wave myocardial infarction and randomized them
to 16 weeks of atorvastatin 80 mg or placebo once daily
[5]. The major exclusion criteria were: total cholesterol
level greater than 270 mg/dL; Q-wave myocardial infarc-
tion on admission or during the previous month; and,
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sion, during the index hospitalization or anticipated fol-
lowing hospital discharge. The primary efficacy endpoint
was a composite of death, non-fatal myocardial infarc-
tion, resuscitated sudden cardiac death or emergent rehos-
pitalization for worsening symptomatic myocardial
ischemia. Secondary endpoints included stroke, worsen-
ing heart failure, need for coronary revascularization and
change in lipid levels throughout the study. On average,
patients were 65 years of age, approximately 65% were
men, 86% Caucasian and the mean baseline low density
lipoprotein (LDL) cholesterol level was 124 mg/dL. Ator-
vastatin treatment was associated with a 2.6% absolute re-
duction in the risk of the primary endpoint (14.8% vs.
17.4%; RR relative risk [RR] 0.84, 95% confidence interval
[CI] 0.70–1.00, p = 0.048). This reduction was primarily
driven by the 2.2% absolute reduction in incidence of
emergent rehospitalization for symptomatic myocardial
ischemia (6.2% vs. 8.4%; RR 0.74, 95% CI 0.57–0.95, p =
0.02). The risk of death, nonfatal myocardial infarction
and resuscitated sudden cardiac death were each no differ-
ent between the two groups. While there were no signifi-
cant differences in the incidence of worsening heart
failure or need for coronary revascularization, atorvastatin
did reduce the incidence of fatal or non-fatal stroke by
0.8% (0.8% vs. 1.6%; RR 0.50, 95% CI 0.26–0.99, p =
0.045). Atorvastatin also significantly reduced total and
LDL cholesterol and triglyceride levels but did not signifi-
cantly change high density lipoprotein (HDL) cholesterol
by 16 weeks. By 16 weeks, the adjusted mean LDL choles-
terol decreased to 72 mg/dL in atorvastatin-treated pa-
tients but increased to 135 mg/dL among placebo-treated
patients. No serious adverse events occurred as the result
of treatment with atorvastatin, although reversible liver
transaminase elevation more than three times the upper
limit of normal occurred in 2.5% of atorvastatin-treated
versus 0.6% of placebo-treated patients (p < 0.001).
The MIRACuLous
The efficacy and safety findings from MIRACL were
unique for a number of reasons. Although lipid-lowering
therapy was associated with a significantly lower mortality
when initiated early after an acute coronary syndrome in
two large observational studies [6,7], MIRACL was the
first randomized trial to suggest that statins confer clinical
benefits in this setting. It was also the first trial to identify
a short-term (ie, within 16 weeks) clinical benefit from
statin therapy; in previous secondary prevention trials, the
benefit of statin therapy was not evident for one to two
years. And, while clinical trial safety endpoints may be
considered less glamorous, MIRACL's most important
contribution may have been that high-dose statin therapy
was not associated with serious harm, despite its use in the
unstable setting. Earlier secondary prevention statin trials
had excluded patients with unstable coronary syndromes
largely out of theoretical concern that statin-mediated re-
ductions in vascular smooth muscle cell proliferation
might destabilize healing plaque. That no harm resulted
from this aggressive treatment strategy should allay theo-
retical fears and by doing so remove a major obstacle to
the inpatient initiation of lipid-lowing therapy after coro-
nary events.
The not so MIRACuLous
Despite these unique and important findings, there were
a number of inherent study limitations worth noting. First
and foremost, the possibility of a null treatment effect
cannot be ignored given the wide confidence intervals
(and hence marginally significant p value of 0.048) for the
effect of atorvastatin on the primary efficacy endpoint.
Furthermore, while the number of patients lost to follow
up was small, if adverse events had occurred in those treat-
ed with atorvastatin (n = 3) but not placebo (n = 8), the
overall trial results may have been neutral rather than pos-
itive.
The types of events prevented in MIRACL are also worth
noting. While rehospitalization for recurrent myocardial
ischemia is an important determinant of quality of life
and health care costs, other important endpoints were not
significantly affected (eg, death, myocardial infarction, re-
suscitated sudden cardiac death, worsening heart failure,
need for coronary revascularization, etc). The question of
whether statins can prevent these and other adverse events
when initiated soon after an acute coronary syndrome will
require further study.
The short duration of follow-up is also particularly trou-
bling. While it is impressive that a clinical benefit was re-
alized after only 16 weeks of statin therapy, the increased
risk of adverse clinical events persists throughout the year
following an acute coronary syndrome. Without longer
clinical follow up, it is not possible to assess the interme-
diate-term effect (if any) of atorvastatin on hard end-
points such as death or myocardial infarction. To do so
would be critical in light of the lack of effect on these im-
portant endpoints at 16 weeks. Unfortunately, no late
clinical follow up is planned.
There were also a number of limitations that may have
hampered the study's generalizability. First, patients who
underwent recent revascularization or in whom it was
planned were excluded. Specifically, patients who under-
went percutaneous transluminal coronary angioplasty
(PTCA) or coronary artery bypass graft (CABG) surgery
within the previous three or six months respectively were
not eligible for inclusion. The investigators reasoned that
recurrent ischemic events in this population were likely to
result from restenosis or bypass graft closure and that stat-
ins would be less likely to affect these processes [8]. Nev-Page 2 of 5
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of statin therapy early after coronary revascularization [9–
11]. Furthermore, a number of recent trials have suggested
that higher risk patients with non-ST elevation acute cor-
onary syndromes fair better when an early invasive strate-
gy is applied [12–14] and it is not uncommon for patients
to be treated in this fashion. Second, patients with Q-wave
myocardial infarction were not eligible for enrollment be-
cause it was felt that statins would not influence the devel-
opment of important prognostic determinants such as left
ventricular systolic dysfunction, ventricular arrhythmias
or mechanical complications [5]. Nevertheless, patients
who develop electrocardiographic Q-waves represent a
substantial proportion of all patients with myocardial in-
farction. While their short-term risk following hospital
discharge is lower relative to those with a non-Q-wave
myocardial infarction, it is still much greater than in pa-
tients with stable coronary disease, and the need for sec-
ondary prevention in this population is equally
important. Third, despite the high risk nature of enrolled
patients (ie, electrocardiogram [ECG] changes and/or oth-
er objective evidence of ischemia), the rate of platelet glyc-
oprotein IIb/IIIa inhibitor utilization was quite low
(1.1%). Such therapy appears to be cost effective[15,16],
especially among high risk patients and is recommended
under current American College of Cardiology/American
Heart Association guidelines [17]. Fourth, it may not be
possible to ascertain whether these findings apply to all
patients with recent acute coronary syndromes regardless
of baseline lipid levels. The small difference in number of
primary endpoint events between atorvastatin and place-
bo groups make it difficult to dissect the relationship be-
tween baseline lipid levels and treatment effect further.
Consequently, it remains uncertain whether one can ex-
trapolate the MIRACL trial results to those who undergo
coronary revascularization shortly before or after a coro-
nary event, who present with a Q-wave myocardial infarc-
tion, who are treated with platelet glycoprotein IIb/IIIa
inhibitors, or who have relatively low admission LDL cho-
lesterol levels.
Time to change current practice
Although MIRACL and the two aforementioned cohort
studies suggest that lipid-lowering agents exert short-term
clinical benefits when initiated soon after an acute coro-
nary syndrome, this remains an open question. Even if
these findings are not confirmed after further study, one
could still make a compelling argument that lipid-lower-
ing therapy (barring contraindications) should be initiat-
ed early and universally in patients who present with an
acute coronary syndrome: First, the long-term safety and
effectiveness of statins for the secondary prevention of sta-
ble coronary disease is well-established [1–3]; Second, as
evidenced by MIRACL, these agents are safe when initiat-
ed at the time of hospitalization for an acute coronary syn-
drome; Third, the in-hospital initiation of lipid-lowering
therapy appears to promote greater long-term utilization
of these agents [18–21]. Finally, although lipid levels may
be unreliable in the setting of an acute coronary syndrome
(excepting total :HDL and LDL:HDL cholesterol ratios
[22]) the overwhelming majority of patients with coro-
nary disease will ultimately require both pharmacologic
and non-pharmacologic lipid-lowering interventions to
attain recommended cholesterol targets [23–25]; newer
guidelines are even more stringent [26]. Furthermore,
data from the recently presented Heart Protection Study
suggest that clinical benefits may accrue independent of
baseline cholesterol level [4]. Thus, to withhold lipid-low-
ering therapy from patients who present with an acute
coronary syndrome would be to accept the status quo, and
to date our efforts at cholesterol lowering in the secondary
prevention setting have been dismal [27,28].
More MIRACLes ahead?
The ascertainment and quantification of any incremental
benefit conferred by statin therapy initiated early after an
acute coronary syndrome will require confirmation. There
is currently only one ongoing randomized placebo-con-
trolled trial of early versus delayed statin therapy in this
setting, A-2-Z (Aggrastat to Zocor, Merck) [29]. The A-2-Z
study is evaluating the efficacy of early treatment with
simvastatin in 4,500 patients following an episode of un-
stable angina or a non-Q wave myocardial infarction. In
the first four months, patients will be randomized to sim-
vastatin 40 mg daily or placebo. Thereafter, those patients
treated with simvastatin in the first phase will receive 80
mg of simvastatin daily and those treated with placebo, 40
mg of simvastatin daily. The primary composite endpoint
is the occurrence of cardiovascular death, non-fatal myo-
cardial infarction, or rehospitalization for an acute coro-
nary syndrome (ACS) at one year. If A-2-Z demonstrates
significant reductions in the incidence of adverse events
during the first four months, it would suggest an incre-
mental clinical benefit from initiating these agents early
after an acute coronary syndrome. If benefits accrue, but
do so later during follow up, it would be difficult to dis-
criminate between the effects of more aggressive vs. earlier
lipid lowering therapy.
The Pravastatin or Atorvastatin Evaluation and Infection
Therapy (PROVE IT) trial is looking at 4,000 patients
within 10 days of an acute coronary syndrome and rand-
omizing them to either pravastatin 40 mg or atorvastatin
80 mg daily [29]. Patients will be observed over at least
1.5 years for the occurrence of myocardial infarction or
other cardiovascular events. Unlike, MIRACL and the A-2-
Z trials, this study will not assess the efficacy of early statin
therapy after an acute coronary syndrome; rather, it will
examine the role of more vs. less aggressive lipid-lowering
in this setting.Page 3 of 5
(page number not for citation purposes)
Current Controlled Trials in Cardiovascular Medicine 2002, 3 http://cvm.controlled-trials.com/content/3/1/3In 2002, many would consider it unethical to withhold
statins from patients with established coronary disease.
This makes it unlikely that additional placebo-controlled
trials will be carried out in this area. Future secondary pre-
vention studies should look at patients with stable or un-
stable disease and will need to address the comparative
efficacy of different statins (or newer agents), assess the in-
cremental benefit of combination therapy [30] and deter-
mine whether there is a serum cholesterol 'floor' below
which reductions are unlikely to provide further clinical
benefit.
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